Clinical trial
Outcomes of Patients With Advanced Neuroendocrine Cancer (NEN) Treated With Systemic Treatment: Somatostatin Analogues, Molecular Targeted Therapy, Chemotherapy and Peptide Radioisotope Therapy - a Retrospective Analysis.
NCT04331912 is registered in ClinicalTrials.gov with University of Warmia and Mazury as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Outcomes of Patients With Advanced Neuroendocrine Cancer (NEN) Treated With Systemic Treatment: Somatostatin Analogues, Molecular Targeted Therapy, Chemotherapy and Peptide Radioisotope Therapy - a Retrospective Analysis.
- Lead sponsor
- University of Warmia and Mazury
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- July 1, 2019
- Completion date
- December 31, 2023
- Enrollment
- 100 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.